/
/
/

Accretion Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---56%
---42%
---234%
41%41%41%29%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
LAURUSLABS
CIPLA
DRREDDY
MANKIND
AUROPHARMA
LUPIN
ACCPL-ST
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,746.4₹424466 Cr35.0912.0762.82₹11479 Cr
9,023₹246222 Cr84.1834.04128.41₹2568 Cr
4,580₹176301 Cr80.8316.7297.06₹2163 Cr
1,124.7₹112818 Cr259.4262.53₹5040 Cr
2,036.9₹110823 Cr101.366.829.25₹889 Cr
1,314.6₹107447 Cr31.889.7757.87₹3879 Cr
1,216₹103471 Cr32.115.3263.99₹4196 Cr
2,335₹97850 Cr47.913.7571.08₹1913 Cr
1,662.9₹96836 Cr26.0817.9596.84₹3505 Cr
1,953.2₹89629 Cr16.2130.95154.35₹5333 Cr
193.2₹215 Cr22.21—9.79₹10 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024
———
₹11 Cr₹8 Cr₹4 Cr
₹44 Cr₹7 Cr₹1 Cr
₹44 Cr₹7 Cr₹1 Cr
₹55 Cr₹15 Cr₹5 Cr
₹0₹23 L₹1 Cr
₹86 L₹94 L₹6 Cr
₹27 L₹19 L₹14,000
₹1 Cr₹1 Cr₹7 Cr
———
₹6 Cr₹8 Cr₹7 Cr
₹3 Cr₹4 Cr₹2 Cr
₹9 Cr₹9 Cr₹4 Cr
₹4 Cr₹3 Cr₹2 Cr
₹21 Cr₹23 Cr₹15 Cr
₹77 Cr₹40 Cr₹27 Cr
₹12 Cr₹14 Cr₹13 Cr
———
₹15 Cr₹7 Cr₹5 Cr
₹2 Cr₹100 L₹22 L
₹13 Cr₹6 Cr₹5 Cr
₹20 L₹0₹0
₹31 L₹23 L₹0
₹0₹66,000₹13 L
₹14 Cr₹6 Cr₹5 Cr
———
₹28 Cr₹21 Cr₹14 Cr
₹22 Cr₹12 Cr₹6 Cr
₹4 Cr₹5 L₹9 L
₹2 L₹2 L₹6 L
₹6 Cr₹1 Cr₹2 Cr
₹60 Cr₹33 Cr₹22 Cr
₹40 Cr₹10 Cr₹7 Cr
₹3 Cr₹10 L₹0
₹77 Cr₹40 Cr₹27 Cr
₹47₹19₹14
₹47₹19₹7

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024
₹13 Cr₹10 Cr₹2 Cr
₹2 Cr₹2 Cr₹62 L
-₹26 Cr-₹10 Cr-₹15 Cr
-₹11 Cr₹2 Cr-₹12 Cr
-₹15 Cr-₹62 L-₹12 Cr
-₹9 Cr-₹2 Cr-₹5 Cr
₹27 Cr₹2 Cr₹17 Cr
₹4 Cr-₹4 L₹9 L
₹5 L₹9 L₹0
₹4 Cr₹5 L₹9 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)0.00
Volume (₹)0.00
High (₹)0.00
Upper Circuit202.85
Low (₹)0.00
Lower Circuit183.55
Prev Close193.20
52W High (₹)220.00
Price193.20
52W Low (₹)53.80

Share Market Cap & Key Ratios Overview

M.Cap (₹)214.76 Cr
Div. Yield (%)0.00
PE Ratio22.21
Debt to Equity0.24
Price to Book1.35
Book Value46.91
EPS (TTM)8.70
Face Value10.00
ROE (%)28.72

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ACCPL-STNSE
LTP
1W Low
1W High
Market cap (₹)
1746.4-13.6 (-0.77%)
1725.50
1776.60
4,24,466Cr
9023-317 (-3.39%)
8937.50
9431.50
2,46,222Cr
4580-76.9 (-1.65%)
4551.80
4682
1,76,301Cr
1124.7+7.2 (0.64%)
1107.30
1150.90
1,12,818Cr
2036.9+0.3 (0.01%)
2007.80
2069.20
1,10,823Cr
1314.6+13.6 (1.05%)
1300.20
1333.30
1,07,447Cr
1216+19 (1.59%)
1196.90
1250.70
1,03,471Cr
2335-33.5 (-1.41%)
2317.50
2426.80
97,850Cr
1662.9-30.1 (-1.78%)
1654.10
1715
96,836Cr
1953.2-3.3 (-0.17%)
1925.70
1964.90
89,629Cr
193.2+4.25 (2.25%)
190
198.90
215Cr

Accretion Pharmaceuticals Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Accretion Pharmaceuticals Ltd Quaterly Results Key Takeaways